Hidradenitis suppurativa has come to be associated with systemic inflammation as well as a growing list of comorbidities including acne conglobate.
Efforts are underway to identify new therapeutic methods that can offer improved outcomes for patients with hidradenitis suppurativa.
Clinical trials investigating the efficacy of biologics in treating this condition at Stage 2 and Stage 3 are growing in number and should be considered a front-line treatment option, says this expert.